RxDoctor Payments Data

Michael Parisi, DO

Internal Medicine · McKinney, TXNPI 1447228713

Payments from drug & device makers

$243in general payments, 2019–2025

Across 13 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$56
  • AbbVie$47
  • Bayer$28
  • Intuitive Surgical$25
  • Genentech USA, Inc.$16
  • Analog Devices Inc.$16
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$56
AbbVie2$47
Bayer1$28
Intuitive Surgical1$25
Genentech USA, Inc.1$16
Analog Devices Inc.1$16
Exact Sciences1$15
Nabriva Therapeutics, PLC1$14
Linus Health, Inc.1$13
Lilly USA, LLC1$11

How this compares

$243 in reported general payments places this provider in the 45th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$156,067
Medicare patients
240
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$56,887
FarxigaDapagliflozin Propanediol34$36,439
MounjaroTirzepatide20$29,710
EliquisApixaban22$28,794
JanuviaSitagliptin Phosphate31$26,598
XareltoRivaroxaban23$25,613
ArexvyRsvpref3 Antigen/As01e/Pf24$7,635
Xigduo XrDapaglifloz Propaned/Metformin11$6,494
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,224
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,018
Sevelamer Hcl12$3,226
PaxlovidNirmatrelvir/Ritonavir15$2,858
Rosuvastatin Calcium215$2,835
Lubiprostone29$2,332
Metoprolol Succinate108$2,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$56$56,88745 claims
Lilly USA, LLCMounjaro$11$29,71020 claims
AbbVieArmour Thyroid, Synthroid$47$1,99131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →